Persistent improper upregulation of Th17 and TReg cells in patients with juvenile idiopathic arthritis  by Wu, Shun-An et al.
Journal of Microbiology, Immunology and Infection (2016) 49, 402e408Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEPersistent improper upregulation of Th17
and TReg cells in patients with juvenile
idiopathic arthritis
Shun-An Wu, Kuo-Wei Yeh, Wen-I Lee, Tsung-Chieh Yao,
Jing-Long Huang*Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial
Hospital at Linkou and Chang Gung University, Taoyuan, TaiwanReceived 8 March 2014; received in revised form 19 June 2014; accepted 1 July 2014
Available online 28 August 2014KEYWORDS
Juvenile idiopathic
arthritis;
regulatory T cells/
TReg;
T helper cells/Th17* Corresponding author. Division of A
Hsin Street, Taoyuan, Taiwan.
E-mail address: long@adm.cgmh.o
http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, Taiwan
CC BY-NC-ND license (http://creativeObjectives: Juvenile idiopathic arthritis (JIA) is the most common childhood rheumatic dis-
ease. A break in the balance between Th17 and TReg cells has been reported as an important
factor in the development of autoimmune diseases. This study aimed to analyze peripheral
Th17 and TReg cell levels in patients with JIA.
Methods: The balance of Th17 and TReg cells among active and inactive JIA patients and normal
control subjects were compared. Human peripheral blood mononuclear cells were isolated
from the patients and controls. Surface and intracellular staining for CD4, CD25, Foxp3, IL-
17, Th17, and TReg were analyzed.
Results: Twenty-eight JIA patients, including 12 with active JIA and 16 with inactive JIA, and 20
health controls were analyzed. Patients with active JIA had higher Th17 (1.85  1.15 vs.
1.05  0.72, pZ 0.008) and TReg cells (1.1  0.8 vs. 0.6  0.7, pZ 0.04) levels than those with
inactive JIA. Among active JIA patients, remission days were highly correlated with the
CD4þIL17Aþ Tcell percentage, 276.5 137.40 days (range, 130w 525 days), p< 0.01. Therewere
no differences in Th17/TReg percentage between JIA patients and controls in the peripheral blood.
Conclusions: Th17 and TReg cell levels are elevated in patients with active JIA and there is no
Th17/TReg imbalance. The higher Th17 level predicted longer period to reach disease inactive
stage. Improper Th17 up-regulation might contribute to JIA activation.
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nc-nd/4.0/).llergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, 5, Fu-
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Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in childhood and is defined as local
inflammation in one or more joints persisting for more than
6 weeks and beginning before the age of 16 years.1 The
reason for this autoimmune activation in JIA is unclear. To
date, one of the important mechanisms of this clinically
heterogeneous group of chronic pediatric arthritis with
unknown etiology is characterized by T cell-dependent
inflammation of the synovium, resulting in progressive
cartilage destruction, bone damage, and joint destruction.2
Naı¨ve CD4þ Tcells can differentiate into various subtypes
of helper T cells with distinct functions and cytokine pro-
files. Among the various helper T cell subsets, interleukin
(IL)-17-producing helper T (Th17) cells are distinguished
from Th1 or Th2 cells by their expression of IL-17A, IL-17F,
IL-21, and IL-22.3 IL-17 is a cytokine participating in tissue
inflammation by inducing the expression of proinflammatory
cytokines, chemokines, and matrix metalloproteinases.4
Weaver et al5 reported that IL-17 drives neutrophil differ-
entiation, monocyte activation, and synovial fibroblast
activation, chemokine release, prostaglandin production,
and matrix metalloproteinase synthesis, thereby contrib-
uting to autoimmunity. Moreover, Th17 cells can cooperate
with Th1 cells for interferon-gamma production, further
contributing to the proinflammatory state.6
At present, numerous studies on mice characterize Th17
as effector cells in various settings, including inflammation,
autoimmunity, and immune defense.4 Enhanced IL-17
expression and increased serum IL-17 levels have been
observed in target tissues of patients with various autoim-
mune diseases, such as systemic lupus erythematosus (SLE)
and rheumatoid arthritis (RA).7e9 Elevated IL-1, tumor ne-
crosis factor alpha (TNF-a), and IL-6 levels are reported in
patients with JIA10 and a synergistic interaction between IL-
17, IL-1, and TNF-a leading to synovial fibroblast activation
and cytokine secretion suggests that IL-17 plays a role in the
pathogenesis of joint destruction.11 An excess of Th17 cells
has been detected in adults with RA and in children with JIA,
particularly in those with more advanced disease.12
In contrast to Th17 cells, regulatory T (TReg) cells,
defined by the expressions of CD4, CD25, and the tran-
scription factor forkhead box P3 (FoxP3), have a central
role in protecting an individual from autoimmunity.13 TReg
cells maintain tolerance to self-components by contact-
dependent suppression or by releasing anti-inflammatory
cytokines like IL-10 and transforming growth factor beta
(TGF-b).14 The suppressive effects of TReg cells prevent
autoimmune flare-ups and chronic inflammation.15 Dysre-
gulation of TReg cells are currently considered key factors in
several autoimmune diseases such as type 1 diabetes mel-
litus, multiple sclerosis, inflammatory bowel disease, and
psoriasis.16,17 Some studies suggest that the balance be-
tween Th17 and TReg cells is important in the development/
prevention of inflammatory and autoimmune diseases.16,17
Thus, identifying the detailed relationship between Th17
and TReg cells and interacting molecules is important for
controlling the progression of various diseases.
Although both Th17 cells and TReg cells contribute to the
pathogenesis of autoimmune disease, little is known abouttheir relationship in JIA. Nistala et al18 have indicated that
Th17 cells are highly enriched in the JIA synovium and have
a reciprocal relationship with TReg cells. The present study
aimed to analyze the relationship between JIA and Th17/
TReg cells by quantifying CD4
þ Th17 and CD4þCD25þFoxP3þ
TReg cells in peripheral blood from JIA patients and healthy
controls using surface staining, intracellular cytokine
staining, and flow cytometry analysis. Because JIA flare-up
could lead to severe joint destruction and systemic
involvement as the result of increasing autoimmunity, pa-
tients with JIA were further divided into active and inactive
groups.
Materials and methods
From December 2009 to December 2012, JIA patients on
regular follow up at Chang Gung Memorial Hospital, a ter-
tiary care center in Taiwan, were randomized in this cross-
sectional study. Mononuclear cells were isolated from
paired samples of peripheral blood from patients fulfilling
the International League of Associations for Rheumatology
criteria for JIA and from healthy individuals, for analysis of
Th17 and TReg cells phenotype.
19 Patients with JIA were
categorized into active stage if they had arthritis with or
without systemic features and raised C-reactive protein
(CRP)/erythrocyte sedimentation rate (ESR).20 Active dis-
ease in the polyarticular and oligoarticular onset groups
was defined as at least one joint that had symptoms of
active arthritis (swelling, or if swelling was not present,
limitation of movement, accompanied by pain or tender-
ness on motion, or heat). Active disease in the systemic-
onset group was defined as at least one joint with active
arthritis (as above) or a fever of >38.5C at least 4 days/
week without definable infection or other identifiable
sources other than JIA. Patients with active systemic-onset
juvenile RA (JRA) were further categorized according to the
persistence or absence of systemic features, which were
defined as the presence of a high spiking fever (>38.5C) at
the time of sampling. Remission was defined as the absence
of active synovitis (morning stiffness not exceeding 15 mi-
nutes, no fatigue, no joint pain, no joint tenderness, and no
joint or tendon sheath swelling), as well as normal ESRs
associated with normal serum CRP concentrations during
the previous 3 months.21,22
All of the patients were assessed in terms of clinical
manifestations, disease activity, and treatment regimens.
It is reported that the usage of anti-TNF alpha agents would
decrease Th17 cells in peripheral blood.23 The patients
were excluded in this study if they had received anti-TNF
alpha agents or biologics in the past 6 months. Age-
matched healthy control individuals, who did not have
any chronic disease or medication in the previous year,
were recruited for comparison. The hospital’s ethics com-
mittee approved the study (IRB number: 100-4299A3) and
all of the study participants and their parents provided
informed consent.
Collection and preparation of blood samples
Blood specimens were drawn following an overnight fast for
baseline evaluation. Mononuclear cells were isolated from
Table 1 Clinical characteristics of patients with juvenile
idiopathic arthritis (n Z 28)
Active JIA
(n Z 12)
Inactive
JIA (n Z 16)
Characteristics
Age (y) 18.5  6.54 18.19  6.59
Range (y) 6.87e30.65 8.83e30.12
Duration of disease (y) 8.5  4.56 8.7  5.14
Sex (male/female) 6 vs. 6 7 vs. 9
Systemic type (n Z 4) 1 3
Oligoarticular
type (n Z 14)
5 7
Polyarticular
type (n Z 12)
6 6
Time to remission (d) 276.5  137.40
Remission range (d) 130e525
Current treatment of sample (number/%)
MTX 3 0
NSAIDs 11 6
Prednisolone 2 0
None 0 10
JIA Z juvenile idiopathic arthritis; MTX Z methotrexate;
NSAID Z nonsteroidal anti-inflammatory drug.
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Blood specimens were placed into collection tubes con-
taining 0.2 mL sodium heparin. Peripheral blood mono-
nuclear cells (PBMCs) were prepared by Ficoll density
gradient for analysis using flow cytometry.
Cell preparation
For analysis of Th17 cells, PBMCs were suspended at a den-
sity of 2  106 cells/mL in complete culture medium (RPMI
1640 supplemented with 100 U/mL penicillin, 100 mg/mL
streptomycin, 2 mM glutamine, and 10% heat-inactivated
fetal calf serum, Burlington, Ontario, Canada, Gibco BRL).
The cell suspension was transferred to 24-well plates and
cultures were stimulated using phorbol myristate acetate
(50 ng/mL) plus ionomycin (1 mM) for 4 hours in the presence
of monensin (500 ng/mL, all from Alexis Biochemicals, San
Diego, CA, USA) The incubator was set at 37C under 5% CO2
environment. After 4 hours of culture, the contents of the
wells were transferred to 5-mL sterile tubes. The cells were
then centrifuged at 1500 rpm for 5 minutes.
Surface and intracellular staining for Th17 and TReg
cells
The cells were stained with fluorochrome-conjugated
monoclonal antibodies and their appropriate isotype con-
trols. Cells were aliquoted into tubes and washed once in
phosphate-buffered saline. For Th17 analysis, the cells
were incubated with phycoerythrin (PE) antihuman CD4
(eBioscience, San Diego, CA, USA) at 4C for 20 minutes. For
TReg analysis, the cells were incubated with peridinin
chlorophyll antihuman CD4 and fluorescein isothiocyanate
(FITC) antihuman CD25. After the surface staining, the cells
were stained with FITC antihuman IL-17A for Th17 detec-
tion or PE antihuman FoxP3 for TReg detection after fixation
and permeabilization (BD Cytofix/Cytoperm, San Jose, CA,
USA) according to the manufacturer’s instructions. Isotype
controls were given to enable correct compensation and
confirm antibody specificity. All of the antibodies were
from eBioscience. Stained cells were analyzed by flow
cytometric analysis using a FACS (Fluorescence-Activated
Cell Sorting) cytometer (BD FACSCanto II Flow Cytometry
System, San Jose, CA, USA) equipped with CellQuest soft-
ware (BD Bioscience PharMingen, San Jose, CA, USA). An
isotype-matched control monoclonal antibody was used to
determine nonspecific staining. Expression of cell surface
or intracellular proteins was quantified using flow cytom-
etry (FACSCalibur; BD Biosciences, San Jose, CA, USA) and
data were analyzed using the CellQuest Pro software (BD
Biosciences). The purity of isolated cells, as assessed by
flow cytometry using anti-CD3, anti-CD4, anti-CD25, anti-
IL17A, and anti-FoxP3 antibodies, was >85%.
Statistical analysis
Comparisons of the Th17 and TReg cell percentages and
Th17/TReg ratio were made between the JIA and control
groups. Following international criteria, JIA patients were
divided into active and inactive groups for further evalua-
tion.20 For all major results, 95% confidence intervals (CIs)were given. All comparisons between JIA patients and
controls were made using Student t test. Statistical signif-
icance was set at p  0.05.Results
Twenty-eight patients with JIA and 20 healthy controls
completed the TReg/Th17 phenotype analysis. The mean
age of JIA patients and the controls was 18.2  6.4 years
(range, 7.72e30.41 years) and 19.21  4.22 years (range,
11.09e30.67 years), respectively. There was no significant
difference in age and follow-up duration between these
two groups.
Of the 28 JIA patients, 14 were oligoarticular type, 10
were polyarticular type, and four were systemic type.
Thirteen were male and 15 were female. Twelve patients
had active disease and 16 had inactive disease. Their
characteristics and current medication are shown in
Table 1. Among 12 active JIA patients, all became disease
inactive stage during the follow-up period. The mean
remission duration of active JIA patients was
276.5  137.40 days (range, 130w525 days).
The mean CD4þ T cell percentage was 40.0  8.5% in JIA
patients and 40.8  6.7% in healthy individuals. The mean
CD4þCD3þCD25þ T cell percentage in patients with JIA was
9.2  4.6% (range, 2.8e14.8%) and the mean
CD4þCD25þFoxP3þ T cell percentage was 0.9  0.8% (range,
0e2.4%). Their mean CD4þCD3þIL17Aþ T cell percentage
was 1.52  0.88% (range, 0e3.6%) and their mean Th17/
TReg ratio was 1.71  1.0.
Among the controls, the mean CD4þCD25þFoxP3þ T cell
percentage was 0.8  0.5% (range, 0e2.0%). The mean
CD4þCD3þIL17Aþ T cell percentage was 1.4  1.0% (range,
0e2.7%) and the mean Th17/TReg ratio was 1.75  1.0.
Table 2 Frequencies of surface and intracellular staining of circulating T cells
Cell marker Controls JIA Active JIA Inactive JIA
n Z 20 n Z 28 n Z 12 n Z 16
CD4þ 40.8  6.7 40.0  8.5 40.8  7.9 39.9  9.1
CD4þCD3þCD25þ 8.1  1.8 9.2  4.6 9.2  5.0 9.0  4.3
CD4þCD3þIL17 Aþ 1.4  1.0 1.52  0.88 1.85  1.15 1.05  0.72
CD4þCD25þFoxP3þ 0.8  0.5 0.9  0.8 1.1  0.8 0.6  0.7
Th17/TReg 1.75  1.0 1.71  1.1 1.68  1.0 1.81  1.2
p Controls vs. JIA Active JIA vs. inactive JIA Inactive JIA vs. NC Active JIA vs. NC
CD4þ 0.92 0.83 0.88 0.94
CD4þCD3þCD25þ 0.2 0.49 0.43 0.5
CD4þCD3þIL17Aþ 0.46 0.008* 0.04* 0.25
CD4þCD25þFoxP3þ 0.48 0.04* 0.34 0.29
Th17/TReg 0.27 0.15 0.24 0.54
*p < 0.05.
Active juvenile idiopathic arthritis (JIA) patients had higher Th17 and TReg cell levels than inactive JIA patients (p Z 0.008 and 0.04,
respectively); controls had higher levels of Th17 cells than patients with inactive JIA (p Z 0.04).
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between the JIA and the control groups. In analysis of
CD4þCD25þFoxP3þ T cells (TReg) and CD4
þIL17Aþ T cells
(Th17), there was also no significant difference observed.
There was no significant difference in Th17/TReg ratio be-
tween patients with JIA and healthy controls (p Z 0.27;
Table 2).A 
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Figure 1. (A) Patients with active juvenile idiopathic
arthritis (JIA) had higher levels of both Th17 and TReg cells than
inactive JIA patients (p Z 0.008 and 0.04, respectively); (B)
controls had higher levels of Th17 cells compared to patients
with inactive JIA (p Z 0.04).TReg cells and Th17 cells in active and inactive JIA
To analyze whether disease activity could influence Th17/
TReg balance, the 28 JIA patients were divided into active
and inactive JIA groups. The mean CD4þCD25þ T cell per-
centage in the active JIA and inactive JIA groups was
9.2  5.0% and 9.0  4.3% (pZ 0.49), respectively, and the
mean CD4þIL17Aþ T cell percentage was 1.85  1.15% and
1.05  0.72% (pZ 0.008), respectively (Fig. 1A). The mean
CD4þCD25þFoxP3þ T cell percentage was 1.1  0.8% and
0.6  0.7% (pZ 0.04), respectively (Fig. 1B) and the Th17/
TReg ratio was 1.68  1.0 and 1.81  1.2 (p Z 0.15),
respectively. Taken together, in active JIA patients, the
percentages of TReg and Th17 cells were both higher in the
peripheral blood, but the Th17/TReg ratio did not have any
significant difference. By dividing the JIA patients into
active and inactive stages, the representative flow cytom-
etry figures for Th17 and TReg cells are shown in Fig. 2A and
B, respectively. Among 12 active JIA patients, all became
disease inactive stage during the follow-up period. From
the days of enrollment, among active JIA patients, remis-
sion days were highly correlated with the CD4þIL17Aþ T cell
percentage, 276.5  137.40 days (range, 130e525 days),
p < 0.01 (Fig. 3). The percentage of TReg and the Th17/TReg
ratio did not have any significant difference in remission
duration.
Further analysis was made between patients with active
JIA and the healthy controls. There were no significant
differences in serum Th17 and TReg cell percentages. Thus,
JIA patients might have the same autoimmune status as the
healthy population during the disease inactive stage.
Further comparisons made between patients with inactiveJIA and the healthy controls revealed that patients with
inactive JIA had significantly lower CD4þIL17Aþ T cell per-
centages (p Z 0.04), indicating that inactive JIA patients
had significantly lower Th17 cells than the controls
(Table 2).
Figure 2. Representative flow cytometry figures for Th17 and TReg cells in three subtypes of JIA. (A) Active juvenile idiopathic
arthritis (JIA) patients had higher levels of peripheral Th17 cells than inactive JIA patients; (B) active JIA patients had higher levels
of peripheral TReg cells than inactive JIA patients.
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This study attempted to analyze the association between
Th17-TReg phenotype and JIA patients. There were higher
levels of both Th17 and TReg cells in active JIA patients than
inactive JIA patients (both p < 0.05). The time taken to
reach the remission stage was highly correlated with the
Th17 level in active JIA patients (p < 0.05). There was nosignificant difference in the ratio of Th17/TReg between the
two groups.
IL-17 can stimulate fibroblasts to produce IL-6 and IL-8,
which are both inflammatory cytokines.24 By synergistic
interactions among IL-17, IL-1, and TNF-a, Th17 plays a
major role in synovial fibroblast activation and joint
destruction by cytokine secretion.11 Recent studies have
viewed IL-17-producing Th17 cells as important T cells in
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Figure 3. From the days of enrollment, among active juve-
nile idiopathic arthritis (JIA) patients, remission days were
highly correlated with the CD4þIL17Aþ T cell percentage,
276.5  137.40 days (range, 130e525 days), p < 0.01.
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levels are observed in patients with RA, whose enhanced
IL-6 production results in bone and collagen destruc-
tion.25,26 Improper Th17 accumulation is closely related to
autoimmune disease development. Yang et al27 reported
that disease activity closely correlated with serum Th17
levels. In the present study, the CD4þIL17Aþ level is
significantly higher in patients with active JIA compared to
those with inactive disease (p Z 0.008). The duration to
reach remission stage in active JIA patients was highly
correlated with the peripheral Th17 level in this
studyd276.5  137.40 days (range, 130e525 days),
p < 0.001. Thus, the disease status may exert influence in
the proinflammatory-Th17 pathway and poorly controlled
disease activity may result in unduly elevated Th17 cells,
which may be one mechanism that results in disease pro-
gression. This observation is corroborated by lower Th17
cell activity and peripheral Th17 cells in JIA patients with
inactive disease. At present, dysregulation of TReg cells is
considered a key factor in several autoimmune diseases,
including type 1 diabetes mellitus, multiple sclerosis, SLE,
and RA.16,17 By releasing IL-10 and TGF-b, TReg cells can
maintain tolerance to self-components.14 Most studies
suggest that TReg cells are essential for the control of self-
tolerance, based on the fact that depletion of naturally
occurring TReg cells results in hyperproliferation of effector
T cells and autoimmunity.28,29 However, plenty of studies
have documented that TReg cells accumulate in the synovial
fluid and peripheral blood of patients with RA and JIA.30,31
Nonetheless, inflammation progresses.
Baecher-Allan et al32 indicated that preactivated
responder CD4þ T cells become resistant to regulation by
CD4þCD25þ T cells in vitro. This resistance is dependent on
the strength and duration of the stimulus. The present study
has shown that patients with active JIA have much higher
levels of TReg cells in peripheral blood than those with inac-
tive JIA. There is also no significant difference in TReg cell
concentration between healthy controls and active JIA pa-
tients. Thus, the increase in CD4þCD25þ FoxP3þ TReg cells in
active JIA patientsmay be due to the increasing resistance of
effector T cells to the suppression effects of TReg.Some studies have indicated that during the inactive
stage, JIA patients do not have any symptoms and have the
same immune profile.17 In the present study, none of the16
inactive JIA patients used steroids and only six received
nonsteroidal anti-inflammatory drugs during the enrollment
period (Table 1). There were significantly fewer Th17 cells
in inactive JIA patients than in healthy controls (1.05  0.72
vs. 1.4  1.0) and a lower TReg cell concentration was
observed in inactive JIA patients compared to controls. A
previous study found that the use of immunosuppressants
may suppress immune flare-ups, especially when steroids
with long-lasting and cumulative effects are used.33 Thus,
the much lower concentration of Th17 cells in inactive JIA
patients compared to healthy controls may be attributed to
the use of immunosuppressants. Further evaluation of cu-
mulative steroid dosage among JIA patients revealed no
significant association (data not shown).
Recent evidence indicates that both Th17 cells and
natural TReg cells contribute to the pathogenesis of auto-
immune disease.6e13 Some studies even suggest that the
balance between Th17 and TReg cells is the most important
factor in the development/prevention of inflammatory and
autoimmune diseases.16,17 However, through the present
study, no Th17/TReg imbalance was observed (p Z 0.27).
Instead of TReg cell depletion, both Th17 and TReg upregu-
lation were observed in active JIA patients (both p < 0.05).
TReg cells act as inflammation protectors and many studies
suggest their decrease during disease flare-up. However,
there are many existing materials that indicated improper
TReg cell accumulation in the synovial cavity and blood.
29e31
Taken together, Th17 activation seems to have the domi-
nant role in JIA activation and the upregulation of TReg cells
may be due to increased resistance to effector T cells.
This study has several limitations. First, patients with a
history of JIA were enrolled but no newly-diagnosed JIA and
drug-sparing patients were included to identify drug ef-
fects. Instead, cumulative steroid dose was calculated for
analysis and there was no positive association. Second,
cytokine evaluation to determine if JIA patients have higher
resistance to TReg cell suppression was not carried out.
Lastly, the study involved only a small group of JIA patients,
particularly when considering the active versus inactive
groups and the immunosuppressant medication subgroups.
Patients with active JIA have elevated levels of Th17 and
TReg cells. The higher Th17 level predicted a longer period
to reach disease inactive stage. There is no Th17/TReg
imbalance so improper Th17 upregulation may contribute
to the activation of JIA.Conflicts of interest
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